The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics presents promising data on RTNova™, a novel systemic virotherapy technology designed to target metastatic lung cancer and other advanced cancers by overcoming immune clearance and enhancing therapeutic targeting

Discover More

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa

April 15, 2019

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

RTNova

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

The Journal of Translational Medicine

March 27, 2019

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics Launches Scientific and Medical Advisory Board

January 4, 2019

Press Release

event

NeuroNova

Supernova

RTNova

Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO

January 1, 2019

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

RTNova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

November 7, 2018

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

RTNova

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapies

November 7, 2018

Press Release

Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology

August 17, 2021

Discover More

Press Release

Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma

August 4, 2021

Discover More

Press Release

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

June 9, 2021

Discover More

Press Release

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

December 1, 2020

Discover More

Press Release

Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner, Personalized Stem Cells

August 3, 2020

Discover More

Press Release

Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors

July 1, 2020

Discover More

Publication

event

RTNova

NeuroNova

Supernova

Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy

SITC 2024

November 13, 2024

Publication

event

RTNova

NeuroNova

Supernova

Transforming Tumor Immune Microenvironments with a Novel Systemic Enveloped Oncolytic Virotherapy Targeting All Tumor Sites

ASCO Annual Meeting 2024

June 1, 2024

Publication

event

SuperNova (SNV)

NeuroNova

Supernova

Non-Clinical Evidence Supporting the Upcoming CLD-201 Clinical Trial: Cell-Based Oncolytic Virotherapy for Multiple Solid Tumors

ASCO Annual Meeting 2024

June 1, 2024

Publication

event

NeuroNova (NNV)

NeuroNova

Supernova

Phase 1 Study of Multiple Intracerebral Doses of a Neural Stem Cell-based Oncolytic Virotherapy for Treatment of Recurrent High-grade Gliomas

ASCO Annual Meeting 2024

June 1, 2024

Publication

event

NeuroNova & SuperNova

NeuroNova

Supernova

Stem Cell Platforms for Enhanced Oncolytic Virotherapy

Festival of Biologics

April 16, 2024

Publication

event

NeuroNova & SuperNova

NeuroNova

Supernova

Deciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem Cells

American Association for Cancer Research

April 9, 2024

Media

Good Morning San Diego, Calidi Bio Treatments Discussed

April 13, 2019

Discover More

Media

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

April 12, 2019

Discover More

In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023

Discover More

In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023

Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more

The Newsroom

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Releases Recent Interviews of CEO Allan Camaisa

Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers

Calidi Biotherapeutics Launches Scientific and Medical Advisory Board

Calidi Biotherapeutics, Inc. announces its corporate vision in groundbreaking cancer drug development and appoints Allan Camaisa as CEO

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy Technology

Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to their IND for Treatment of Malignant Glioma

Calidi Biotherapeutics Announces Partnership with GenScript ProBio for Distribution of its SuperNova-1 Technology

Calidi Biotherapeutics Announces European Patent Granted by EPO: Combination Immunotherapy Approach for Treatment of Cancer

Calidi Biotherapeutics Announces FDA Approval for COVID-19 Treatment Manufactured by Partner, Personalized Stem Cells

Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors

Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy

Transforming Tumor Immune Microenvironments with a Novel Systemic Enveloped Oncolytic Virotherapy Targeting All Tumor Sites

Non-Clinical Evidence Supporting the Upcoming CLD-201 Clinical Trial: Cell-Based Oncolytic Virotherapy for Multiple Solid Tumors

Phase 1 Study of Multiple Intracerebral Doses of a Neural Stem Cell-based Oncolytic Virotherapy for Treatment of Recurrent High-grade Gliomas

Stem Cell Platforms for Enhanced Oncolytic Virotherapy

Deciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem Cells

Good Morning San Diego, Calidi Bio Treatments Discussed

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.